Piper Jaffray analyst Edward Tenthoff reiterates an Overweight rating on Crispr Therapeutics after the company and partner Vertex (VRTX) announced Fast Track Designation for CTX001 to treat transfusion-dependent beta thalassemia. The analyst believes Crispr's ex vivo approach and biological rational of targeting fetal hemoglobin "de-risk and differentiate" CTX001 from other gene editing players. And he continues to think that first-in-man CTX001 data this year "will serve as an important driver" for Crispr and the gene editing field. Tenthoff says Crispr Therapeutics remains a top for 2019.